Enpp/Carbonic anhydrase-IN-1
Based on 1 Customer Validation
Enpp/Carbonic anhydrase-IN-1 (compound 1e) is a potent Enpp and carbonic anhydrase inhibitor with IC50s of 1.36, 1.35, 3.00, 0.88, 1.02 μM for NPP1, NPP2, NPP3, CA-II, CA-IX respectively. Enpp/Carbonic anhydrase-IN-1 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonic anhydrase-IN-1 induces Apoptosis.
For research use only. We do not sell to patients.
- Purity: 99.57%
- CAS No.: 2883495-35-8
- Formula: C23H25NO4S
- Molecular Weight:411.51
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Biological Activity
|
CA Ⅱ 0.88 μM (IC50) |
CA IX 1.02 μM (IC50) |
NPP1 1.36 μM (IC50) |
NPP2 1.35 μM (IC50) |
NPP3 3.00 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 786-0 | IC50 |
3.8 μM
Compound: 1e
|
Cytotoxicity against human 786-0 cells assessed as cell growth inhibition
Cytotoxicity against human 786-0 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| A498 | IC50 |
2.04 μM
Compound: 1e
|
Cytotoxicity against human A498 cells assessed as cell growth inhibition
Cytotoxicity against human A498 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| A549 | IC50 |
6.9 μM
Compound: 1e
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition
Cytotoxicity against human A549 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| ACHN | IC50 |
>100 μM
Compound: 1e
|
Cytotoxicity against human ACHN cells assessed as cell growth inhibition
Cytotoxicity against human ACHN cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| BT-549 | IC50 |
3.24 μM
Compound: 1e
|
Cytotoxicity against human BT-549 cells assessed as cell growth inhibition
Cytotoxicity against human BT-549 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| CAKI-1 | IC50 |
7.08 μM
Compound: 1e
|
Cytotoxicity against human CAKI-1 cells assessed as cell growth inhibition
Cytotoxicity against human CAKI-1 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| COLO 205 | IC50 |
0.87 μM
Compound: 1e
|
Cytotoxicity against human COLO 205 cells assessed as cell growth inhibition
Cytotoxicity against human COLO 205 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| DU-145 | IC50 |
>100 μM
Compound: 1e
|
Cytotoxicity against human DU-145 cells assessed as cell growth inhibition
Cytotoxicity against human DU-145 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| HCC 2998 | IC50 |
5.48 μM
Compound: 1e
|
Cytotoxicity against human HCC 2998 cells assessed as cell growth inhibition
Cytotoxicity against human HCC 2998 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| HCT-116 | IC50 |
2.5 μM
Compound: 1e
|
Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition
Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| HCT-15 | IC50 |
1 μM
Compound: 1e
|
Cytotoxicity against human HCT-15 cells assessed as cell growth inhibition
Cytotoxicity against human HCT-15 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| HL-60(TB) | IC50 |
8.39 μM
Compound: 1e
|
Cytotoxicity against human HL-60(TB) cells assessed as cell growth inhibition
Cytotoxicity against human HL-60(TB) cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| HOP-62 | IC50 |
>100 μM
Compound: 1e
|
Cytotoxicity against human HOP-62 cells assessed as cell growth inhibition
Cytotoxicity against human HOP-62 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| HOP-92 | IC50 |
1.87 μM
Compound: 1e
|
Cytotoxicity against human HOP-92 cells assessed as cell growth inhibition
Cytotoxicity against human HOP-92 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| Hs-578T | IC50 |
7.29 μM
Compound: 1e
|
Cytotoxicity against human Hs-578T cells assessed as cell growth inhibition
Cytotoxicity against human Hs-578T cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| HT-29 | IC50 |
0.4 μM
Compound: 1e
|
Cytotoxicity against human HT-29 cells assessed as cell growth inhibition
Cytotoxicity against human HT-29 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| IGROV-1 | IC50 |
>100 μM
Compound: 1e
|
Cytotoxicity against human IGROV-1 cells assessed as cell growth inhibition
Cytotoxicity against human IGROV-1 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| K562 | IC50 |
0.32 μM
Compound: 1e
|
Cytotoxicity against human K562 cells assessed as cell growth inhibition
Cytotoxicity against human K562 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| KM12 | IC50 |
2.1 μM
Compound: 1e
|
Cytotoxicity against human KM12 cells assessed as cell growth inhibition
Cytotoxicity against human KM12 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| LOX IMVI | IC50 |
4.38 μM
Compound: 1e
|
Cytotoxicity against human LOX IMVI cells assessed as cell growth inhibition
Cytotoxicity against human LOX IMVI cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| M14 | IC50 |
7.2 μM
Compound: 1e
|
Cytotoxicity against human M14 cells assessed as cell growth inhibition
Cytotoxicity against human M14 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| Malme-3M | IC50 |
>100 μM
Compound: 1e
|
Cytotoxicity against human Malme-3M cells assessed as cell growth inhibition
Cytotoxicity against human Malme-3M cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| MCF7 | IC50 |
3.26 μM
Compound: 1e
|
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| MDA-MB-231 | IC50 |
3.79 μM
Compound: 1e
|
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| MDA-MB-435 | IC50 |
>100 μM
Compound: 1e
|
Cytotoxicity against human MDA-MB-435 cells assessed as cell growth inhibition
Cytotoxicity against human MDA-MB-435 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| MDA-MB-468 | IC50 |
3.8 μM
Compound: 1e
|
Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition
Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| NCI/ADR-RES | IC50 |
5.75 μM
Compound: 1e
|
Cytotoxicity against human NCI/ADR-RES cells assessed as cell growth inhibition
Cytotoxicity against human NCI/ADR-RES cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| NCI-H226 | IC50 |
27.7 μM
Compound: 1e
|
Cytotoxicity against human NCI-H226 cells assessed as cell growth inhibition
Cytotoxicity against human NCI-H226 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| NCI-H23 | IC50 |
6.68 μM
Compound: 1e
|
Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition
Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| NCI-H322M | IC50 |
>100 μM
Compound: 1e
|
Cytotoxicity against human NCI-H322M cells assessed as cell growth inhibition
Cytotoxicity against human NCI-H322M cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| NCI-H460 | IC50 |
6.1 μM
Compound: 1e
|
Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition
Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| NCI-H522 | IC50 |
4.36 μM
Compound: 1e
|
Cytotoxicity against human NCI-H522 cells assessed as cell growth inhibition
Cytotoxicity against human NCI-H522 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| OVCAR-4 | IC50 |
8.38 μM
Compound: 1e
|
Cytotoxicity against human OVCAR-4 cells assessed as cell growth inhibition
Cytotoxicity against human OVCAR-4 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| OVCAR-5 | IC50 |
>100 μM
Compound: 1e
|
Cytotoxicity against human OVCAR-5 cells assessed as cell growth inhibition
Cytotoxicity against human OVCAR-5 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| OVCAR-8 | IC50 |
>100 μM
Compound: 1e
|
Cytotoxicity against human OVCAR-8 cells assessed as cell growth inhibition
Cytotoxicity against human OVCAR-8 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| PC-3 | IC50 |
2.9 μM
Compound: 1e
|
Cytotoxicity against human PC-3 cells assessed as cell growth inhibition
Cytotoxicity against human PC-3 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| RPMI-8226 | IC50 |
0.4 μM
Compound: 1e
|
Cytotoxicity against human RPMI-8226 cells assessed as cell growth inhibition
Cytotoxicity against human RPMI-8226 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| RXF 393 | IC50 |
5.12 μM
Compound: 1e
|
Cytotoxicity against human RXF 393 cells assessed as cell growth inhibition
Cytotoxicity against human RXF 393 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| SF-268 | IC50 |
>100 μM
Compound: 1e
|
Cytotoxicity against human SF-268 cells assessed as cell growth inhibition
Cytotoxicity against human SF-268 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| SF-295 | IC50 |
8.27 μM
Compound: 1e
|
Cytotoxicity against human SF-295 cells assessed as cell growth inhibition
Cytotoxicity against human SF-295 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| SF-539 | IC50 |
0.96 μM
Compound: 1e
|
Cytotoxicity against human SF-539 cells assessed as cell growth inhibition
Cytotoxicity against human SF-539 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| SK-MEL-2 | IC50 |
>100 μM
Compound: 1e
|
Cytotoxicity against human SK-MEL-2 cells assessed as cell growth inhibition
Cytotoxicity against human SK-MEL-2 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| SK-MEL-28 | IC50 |
>100 μM
Compound: 1e
|
Cytotoxicity against human SK-MEL-28 cells assessed as cell growth inhibition
Cytotoxicity against human SK-MEL-28 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| SK-MEL-5 | IC50 |
3.12 μM
Compound: 1e
|
Cytotoxicity against human SK-MEL-5 cells assessed as cell growth inhibition
Cytotoxicity against human SK-MEL-5 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| SK-OV-3 | IC50 |
>100 μM
Compound: 1e
|
Cytotoxicity against human SK-OV-3 cells assessed as cell growth inhibition
Cytotoxicity against human SK-OV-3 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| SN12C | IC50 |
>100 μM
Compound: 1e
|
Cytotoxicity against human SN12C cells assessed as cell growth inhibition
Cytotoxicity against human SN12C cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| SNB-19 | IC50 |
>100 μM
Compound: 1e
|
Cytotoxicity against human SNB-19 cells assessed as cell growth inhibition
Cytotoxicity against human SNB-19 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| SNB-75 | IC50 |
7.16 μM
Compound: 1e
|
Cytotoxicity against human SNB-75 cells assessed as cell growth inhibition
Cytotoxicity against human SNB-75 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| SR | IC50 |
0.58 μM
Compound: 1e
|
Cytotoxicity against human SR cells assessed as cell growth inhibition
Cytotoxicity against human SR cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| SW-620 | IC50 |
1.97 μM
Compound: 1e
|
Cytotoxicity against human SW620 cells assessed as cell growth inhibition
Cytotoxicity against human SW620 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| T47D | IC50 |
3.57 μM
Compound: 1e
|
Cytotoxicity against human T47D cells assessed as cell growth inhibition
Cytotoxicity against human T47D cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| TK-10 | IC50 |
>100 μM
Compound: 1e
|
Cytotoxicity against human TK-10 cells assessed as cell growth inhibition
Cytotoxicity against human TK-10 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| U-251 | IC50 |
4.81 μM
Compound: 1e
|
Cytotoxicity against human U-251 cells assessed as cell growth inhibition
Cytotoxicity against human U-251 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| UACC-257 | IC50 |
13.5 μM
Compound: 1e
|
Cytotoxicity against human UACC-257 cells assessed as cell growth inhibition
Cytotoxicity against human UACC-257 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| UACC-62 | IC50 |
6.47 μM
Compound: 1e
|
Cytotoxicity against human UACC-62 cells assessed as cell growth inhibition
Cytotoxicity against human UACC-62 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
| UO-31 | IC50 |
18.7 μM
Compound: 1e
|
Cytotoxicity against human UO-31 cells assessed as cell growth inhibition
Cytotoxicity against human UO-31 cells assessed as cell growth inhibition
|
[PMID: 36470105] |
Enpp/Carbonic anhydrase-IN-1 (compound 1e) (0-100 µM; ) inhibits some cancer cells growth with IC50s of 0.32, 0.40, 0.58, 0.87, 0.40, 0.96 µM for K-562, RPMI-8226, SR, COLO 205, HT-29, SF-539 cells, respectively[1].
Enpp/Carbonic anhydrase-IN-1 (0-2 µM) shows low cytotoxic against normal breast epithelial cells (HME1) and normal skin fibroblast cells (F180) with IC50s of > 50 μM[1].
Enpp/Carbonic anhydrase-IN-1 (0.32, 0.64 µM) induces apoptosis in a dose-dependent manner at K-562 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:K-562, RPMI-8226, SR, COLO 205, HT-29, SF-539 cells
-
Concentration:0-100 µM
-
Incubation Time:
-
Result:Inhibited the cell growth with IC50s of 0.32, 0.40, 0.58, 0.87, 0.40, 0.96 µM for K-562, RPMI-8226, SR, COLO 205, HT-29, SF-539 cells, respectively.
-
Cell Line:K-562 cells
-
Concentration:0.32, 0.64 µM
-
Incubation Time:
-
Result:Induced apoptosis in a dose-dependent manner.
Chemical Information
-
CAS No. 2883495-35-8
-
Appearance Solid
-
Molecular Weight 411.51
-
Formula C23H25NO4S
-
Color White to light yellow
-
SMILES
O=S(C1=CC=CC=C1)(OC2=CC=C(C=C2)NC(C34CC5CC(C4)CC(C3)C5)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 100 mg/mL (243.01 mM; ultrasonic and warming and heat to 50°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.08 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4301 mL | 12.1504 mL | 24.3007 mL | 60.7519 mL |
| 5 mM | 0.4860 mL | 2.4301 mL | 4.8601 mL | 12.1504 mL | |
| 10 mM | 0.2430 mL | 1.2150 mL | 2.4301 mL | 6.0752 mL | |
| 15 mM | 0.1620 mL | 0.8100 mL | 1.6200 mL | 4.0501 mL | |
| 20 mM | 0.1215 mL | 0.6075 mL | 1.2150 mL | 3.0376 mL | |
| 25 mM | 0.0972 mL | 0.4860 mL | 0.9720 mL | 2.4301 mL | |
| 30 mM | 0.0810 mL | 0.4050 mL | 0.8100 mL | 2.0251 mL | |
| 40 mM | 0.0608 mL | 0.3038 mL | 0.6075 mL | 1.5188 mL | |
| 50 mM | 0.0486 mL | 0.2430 mL | 0.4860 mL | 1.2150 mL | |
| 60 mM | 0.0405 mL | 0.2025 mL | 0.4050 mL | 1.0125 mL | |
| 80 mM | 0.0304 mL | 0.1519 mL | 0.3038 mL | 0.7594 mL | |
| 100 mM | 0.0243 mL | 0.1215 mL | 0.2430 mL | 0.6075 mL |